NanoViricides develops broad-spectrum antiviral drug to combat severe flu season

NanoViricides is highlighting the need for broad-spectrum antivirals amid the current severe flu season, with over 15 million illnesses and 7,400 deaths reported. The company's drug candidate, NV-387, targets a host cell feature used by over 90% of human pathogenic viruses and has shown activity against Influenza A/H3N2, RSV, and coronaviruses in animal studies. NanoViricides plans a Phase II clinical trial to evaluate NV-387 as a potential first-line therapy for respiratory viral infections, with a potential market exceeding $20 billion.